Eli Lilly and Company (NYSE:LLY) Shares Bought by Family Legacy Inc.

Family Legacy Inc. increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.8% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 7,915 shares of the company’s stock after buying an additional 217 shares during the quarter. Eli Lilly and Company comprises 2.1% of Family Legacy Inc.’s holdings, making the stock its 6th largest position. Family Legacy Inc.’s holdings in Eli Lilly and Company were worth $6,231,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the stock. Principal Financial Group Inc. raised its position in shares of Eli Lilly and Company by 5.3% during the 3rd quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock valued at $1,070,698,000 after buying an additional 60,306 shares during the period. Tradition Wealth Management LLC raised its stake in shares of Eli Lilly and Company by 14.0% in the 3rd quarter. Tradition Wealth Management LLC now owns 1,403 shares of the company’s stock valued at $1,243,000 after acquiring an additional 172 shares during the period. Timber Creek Capital Management LLC boosted its position in shares of Eli Lilly and Company by 0.7% during the 3rd quarter. Timber Creek Capital Management LLC now owns 12,632 shares of the company’s stock worth $11,191,000 after purchasing an additional 86 shares during the period. Plotkin Financial Advisors LLC acquired a new stake in Eli Lilly and Company in the 3rd quarter valued at approximately $845,000. Finally, Erste Asset Management GmbH acquired a new stake in shares of Eli Lilly and Company in the third quarter valued at $35,618,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Activity

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. This trade represents a 14.62 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Stock Down 0.2 %

Shares of LLY stock opened at $820.30 on Monday. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The stock has a fifty day moving average price of $844.31 and a 200 day moving average price of $835.77. Eli Lilly and Company has a one year low of $711.40 and a one year high of $972.53. The stock has a market cap of $777.78 billion, a P/E ratio of 70.05, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company declared that its board has authorized a share buyback plan on Monday, December 9th that authorizes the company to repurchase $15.00 billion in shares. This repurchase authorization authorizes the company to purchase up to 2% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on LLY. Bank of America reiterated a “buy” rating and issued a $997.00 target price on shares of Eli Lilly and Company in a report on Tuesday, December 10th. StockNews.com upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Wells Fargo & Company increased their target price on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. Morgan Stanley set a $1,146.00 price target on Eli Lilly and Company in a research note on Thursday, March 6th. Finally, Berenberg Bank set a $970.00 price target on Eli Lilly and Company in a research report on Thursday, January 16th. Three investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $1,009.72.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.